About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 783528, 13 pages
http://dx.doi.org/10.1155/2011/783528
Review Article

Clinical Therapeutics in Pregnancy

1Department of Obstetrics and Gynecology, Washington Hospital Center, Washington, DC 20010, USA
2Eunice Kennedy Shriver National Institute of Child Health and Human Development , NIH, Bethesda, MD 10892, USA

Received 22 October 2010; Accepted 3 May 2011

Academic Editor: Farhad Kamali

Copyright © 2011 Maisa N. Feghali and Donald R. Mattison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy.